创美药业2023中期报告

CharmacyPharmaceutical Co., Ltd.(the “Company” or “We”)(stockcode:2289.HK)is principally engaged in thepharmaceuticaldistribution business.It mainly distributeswesternmedicine,Chinese patent medicine and healthcareproducts to downstream distributors and retail terminals,whileconducting dealings in the third-party logistics business ofmedicinesand providing pharmaceutical products relatedconsulting services. Founded in 2000, over the past 23 years ofrapiddevelopment,it has become one of the leadingpharmaceutical distributors in the Southern China region. TheCompanyadheres to the market strategy of“IntensiveEngagement in Guangdong Province and Extensive Coverageacross Surrounding Areas”, based in Shantou, it has establishedsubsidiariesin Guangzhou,Zhuhai,Huizhou,Foshan andShenzhen, and has four modern pharmaceutical logistics centres,all equipped with professional marketing service team andtransportationteams,and has a highly efficient deliverymechanism of delivering pharmaceuticalproducts three times perday for customers within a radius of 10 kilometers, twice per dayfor customers within a radius of 50 kilometers and once per dayfor those within a radius of 250 kilometersfor non-tendermarkets. In addition, the Company has a modern informationsystem that covers the entire supply chain for pharmaceuticaldistribution,including procurement,sales,warehousing,transportationand delivery. Apart from that,the Companyoperates its own B2Be-commerce platform “Charmacy e-Medicine” (創美e藥), a platform for customers to place orders,make inquires and payment online, etc. In 2022, the Companyranked the 38th among the top 100 PRC wholesalers in respectof revenue generated from the principal business. The Companyranked the 6th amongthe pharmaceutical distribution businessesin Guangdong Province. 創美藥業股份有限公司（「本公司」或「公司」或「我們」）（股份代號：2289.HK）主營醫藥分銷業務，主要向下游分銷商和零售終端分銷西藥、中成藥、保健品等產品，同時也開展第三方物流服務，並提供醫藥產品諮詢服務。公司創立於2000年，經過23年的快速發展，已成長為華南地區領先的醫藥分銷商之一。公司堅持「深耕廣東，輻射周邊」的市場戰略，立足於汕頭，在廣州、珠海、惠州、佛山及深圳成立子公司，並擁有四個現代化醫藥物流中心，專業的營銷服務團隊以及運輸服務團隊，對非招標市場實行「半徑10公里內一日三配、50公里內一日兩配、250公里內一日一配」的高效配送機制。公司具有現代化信息系統，涵蓋整個醫藥分銷供應鏈，包括採購、銷售、倉儲、運輸及交付等。公司同時運營自建的B2B電子商務平台：「創美e藥」，供客戶線上下單、查詢及支付等。公司於2022年全國批發企業主營業務收入前100位排序第38位。公司於廣東省醫藥流通企業排名第6位。 2023年上半年，憑藉良好的倉儲配送能力，本公司獲得由藥鏈圈認證中心頒發的2022-2023年度醫藥物流配送 優 秀 企 業 （ 連 續3年 獲 得 ） 、2022-2023年度現代醫藥物流技術試驗基地（中心）（連續2年獲得）、2022-2023年度醫藥冷鏈最佳物流中心 （ 基 地 ） （ 連 續5年 獲 得 ） 、2022-2023年度醫藥冷鏈物流服務推 In the first half of 2023, thanks to its excellent warehousing anddeliverycapabilities,our Company was recognized as anExcellent Pharmaceutical Logistics andDeliveryEnterprise in2022-2023 by the Pharmaceutical Chain Circle CertificationCenter (for 3 consecutive years), a Modern PharmaceuticalLogistics Technology Test Base(Center) in 2022-2023 (for 2consecutive years), and the Best Pharmaceutical Cold ChainLogistics Center (Base) in 2022-2023 (for 5 consecutive years),a Recommended Enterprise for Pharmaceutical Cold Chain 薦企業（連續4年獲得）、獲得由中國（廣州）國際物流裝備與技術展會組委會頒發的2022-2023年度中國物流行業金螞蟻創新獎（連續6年獲得）。憑藉良好的信譽與優質的服務，本公司獲得由全國工商聯醫藥商會頒發的2022-2023年度中國醫藥商業百強企業，獲得第四屆醫藥金石獎 ·2023年 度 最 佳 醫 藥 營 銷 團 隊獎。 Logistics Services in 2022-2023 (for 4 consecutive years), andawarded the China Logistics Industry ‘Golden Ant’ InnovationAward in 2022-2023 by the Organizing Committee of China(Guangzhou) International Logistics Equipment and TechnologyExhibition (for 6 consecutive years).With a good reputation andhigh-quality services, the Company was recognized as one of theTop 100 Chinese Pharmaceutical Commercial Enterprises in2022-2023 by the Pharmaceutical Chamber of Commerce underthe All-China Federation of Industry and Commerce, and wonthe4th Pharmaceutical Golden Stone Award and the BestPharmaceutical Marketing Team Award in 2023. 公司資料Corporate Information1財務摘要Financial Summary5管理層討論及分析Management Discussion and Analysis6其他資料Other Information25未經審核中期財務報表TheUnaudited Interim Financial Statements31未經審核合併資產負債表Unaudited Consolidated Balance Sheet32未經審核母公司資產負債表Unaudited Balance Sheet of the Parent Company35未經審核合併利潤表Unaudited Consolidated Income Statement37未經審核母公司利潤表Unaudited IncomeStatement of the Parent Company39未經審核合併現金流量表Unaudited Consolidated Statement of Cash Flow44未經審核母公司現金流量表Unaudited Statement of Cash Flow of the Parent Company43未經審核合併股東權益變動表Unaudited Consolidated Statement of Changes inShareholders’Equity45未經審核母公司股東權益變動表Unaudited Statement of Changes inShareholders’Equity of the Parent Company48未經審核中期財務報表附註Notes ToThe Unaudited Interim Financial Statements51 * DIRECTORS *董事 Executive Directors 執行董事 姚創龍(董事會副主席)（註1）鄭玉燕張寒孜 Yao Chuanglong (Vice-chairman of the Board)(Note 1) Zheng Yuyan Zhang Hanzi Non-executive Directors 非執行董事 嚴京斌（董事會主席）（註2）付征徐飛（註3） Yan Jingbin (Chairman of the Board)(Note 2) Fu ZhengXu Fei(Note 3) 獨立非執行董事 Independent non-executive Directors 尹智偉李漢國（註4）關鍵（又稱關蘇哲） Guan Jian (also known as Guan Suzhe) * SUPERVISORS *監事 朱明洪（主席）（註6）張玲（註5）鄭禧玥 Zhu Minghong (Chairman)(Note 6)Zhang Ling（註5）Zheng Xiyue * JOINT COMPANY SECRETARIES *聯席公司秘書 黃慧玲姚潔晞 *審核委員會（註